Funding
TRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push that number even higher.
Matchpoint’s lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year.
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
Forbion participated in the November 2025 series B round of Gate Bioscience, which earlier this week inked an up to $870 million deal extension with Eli Lilly.
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked assets, as well as AI-driven drugmakers.
The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.
Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.
Basecamp Research joins the growing group of AI-forward biotechs that in recent months have brought in notable sums from investors, including Isomorphic Labs and Enveda.
Biotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.
PRESS RELEASES